What is claimed is:

1. A compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

A is -C(O)-, -C(S)-, -$CH_2$-, -CH($C_1$-$C_4$ alkyl)-, or -C($C_1$-$C_4$ alkyl)($C_1$-$C_4$ alkyl)-;

n is an integer ranging from 0 to 3;

each $R_1$ is independently -($C_1$-$C_3$)alkyl, -O-($C_1$-$C_3$)alkyl, -halo, -C(halo)$_3$, -CH(halo)$_2$, -$CH_2$(halo), -$NO_2$, -OH, or -CN;

when A is -$CH_2$-, -CH($C_1$-$C_4$ alkyl)-, or -C($C_1$-$C_4$ alkyl)($C_1$-$C_4$ alkyl)-, then $R_2$ is -phenyl, -naphthyl, or -($C_{14}$)aryl, each of which is unsubstituted or substituted with one or more $R_4$ groups, or, when A is -C(O)- or -C(S)-, then $R_2$ is

(i) -H, -($C_1$-$C_{10}$)alkyl, -($C_2$-$C_{10}$)alkenyl, -($C_2$-$C_{10}$)alkynyl, -($C_3$-$C_{10}$)cycloalkyl, -($C_8$-$C_{14}$)bicycloalkyl, -($C_8$-$C_{14}$)tricycloalkyl, -($C_5$-$C_{10}$)cycloalkenyl, -($C_8$-$C_{14}$)bicycloalkenyl, -($C_8$-$C_{14}$)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which, other than -H, is unsubstituted or substituted with one or more $R_5$ groups, or

(ii) -phenyl, -naphthyl, -($C_{14}$)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more $R_4$ groups;

p is an integer ranging from 0 to 2;

each $R_3$ is independently -OH, -halo, $-NO_2$, -CN, $-NH_2$, $-(C_1-C_3)$alkyl, or $-CH_2OH$;

each $R_4$ is independently $-(C_1–C_6)$alkyl, $-(C_2–C_6)$alkenyl, $-(C_2–C_6)$alkynyl, $-(C_3–C_8)$cycloalkyl, $-(C_5–C_8)$cycloalkenyl, -phenyl, $-(C_3–C_5)$heterocycle, $-C(halo)_3$, $-CH(halo)_2$, $-CH_2(halo)$, -CN, -OH, -halo, $-N_3$, $-NO_2$, $-N(R_6)_2$, $-CH=NR_6$, $-NR_6OH$, $-COR_6$, $-C(O)OR_6$, $-OC(O)R_6$, $-OC(O)OR_6$, $-SR_6$, $-S(O)R_6$, or $-S(O)_2R_6$;

each $R_5$ is independently -CN, -OH, -halo, $-N_3$, $-NO_2$, $-N(R_6)_2$, $-CH=NR_6$, $-NR_6OH$, $-COR_6$, $-C(O)OR_6$, $-OC(O)R_6$, $-OC(O)OR_6$, $-SR_6$, $-S(O)R_6$, or $-S(O)_2R_6$; and

each $R_6$ is independently -H, $-(C_1–C_6)$alkyl, $-(C_2–C_6)$alkenyl, $-(C_2–C_6)$alkynyl, $-(C_3–C_8)$cycloalkyl, $-(C_5–C_8)$cycloalkenyl, -phenyl, $-(C_3–C_5)$heterocycle, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$; and

each halo is independently -F, -Cl, -Br, or -I.

2. The compound of claim 1, wherein p is 0 or 1.

3. The compound of claim 1, wherein A is $-CH_2-$.

4. The compound of claim 1, wherein A is $-CH(C_1-C_4$ alkyl)-.

5. The compound of claim 1, wherein A is $-C(C_1-C_4$ alkyl)$(C_1-C_4$ alkyl)-.

6. The compound of claim 1, wherein A is -C(O)-.

7. The compound of claim 6, wherein $R_2$ is -H, $-(C_1-C_{10})$alkyl, $-(C_2-C_{10})$alkenyl, $-(C_2-C_{10})$alkynyl, $-(C_3-C_{10})$cycloalkyl, $-(C_8-C_{14})$bicycloalkyl, $-(C_8-C_{14})$tricycloalkyl, $-(C_5-C_{10})$cycloalkenyl, $-(C_8-C_{14})$bicycloalkenyl, $-(C_8-C_{14})$tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more $R_5$ groups.

8. The compound of claim 6, wherein $R_2$ is -phenyl, -naphthyl, -($C_{14}$)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more $R_4$ groups.

9. The compound of claim 8, wherein $R_2$ is -phenyl.

10. The compound of claim 9, wherein the phenyl is substituted in its 4-position with an $R_4$ group.

11. The compound of claim 1, wherein A is -C(S)-.

12. The compound of claim 11, wherein $R_2$ is -H, -($C_1$-$C_{10}$)alkyl, -($C_2$-$C_{10}$)alkenyl, -($C_2$-$C_{10}$)alkynyl, -($C_3$-$C_{10}$)cycloalkyl, -($C_8$-$C_{14}$)bicycloalkyl, -($C_8$-$C_{14}$)tricycloalkyl, -($C_5$-$C_{10}$)cycloalkenyl, -($C_8$-$C_{14}$)bicycloalkenyl, -($C_8$-$C_{14}$)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more $R_5$ groups.

13. The compound of claim 11, wherein $R_2$ is -phenyl, -naphthyl, -($C_{14}$)aryl, or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more $R_4$ groups.

14. The compound of claim 13, wherein $R_2$ is -phenyl.

15. The compound of claim 14, wherein the phenyl is substituted in its 4-position with an $R_4$ group.

16. The compound of claim 1 having the formula (Ia):



(Ia)

or a pharmaceutically acceptable salt thereof, wherein $R_1$ and $R_1$' are independently -H, -($C_1$-$C_3$)alkyl, -O-($C_1$-$C_3$)alkyl, -halo, -C(halo)$_3$, -CH(halo)$_2$, -$CH_2$(halo), -$NO_2$, -OH, or -CN.

17. The compound of claim 16, wherein $R_1$ and $R_1$' are independently -($C_1$-$C_3$)alkyl, -O-($C_1$-$C_3$)alkyl, or -halo.

18. The compound of claim 17, wherein A is -C(O)-.

19. The compound of claim 17, wherein A is -C(S)-.

20. The compound of claim 17, wherein A is -$CH_2$-.

21. The compound of claim 17, wherein A is -CH($C_1$-$C_4$ alkyl)-.

22. The compound of claim 17, wherein A is -C($C_1$-$C_4$ alkyl)($C_1$-$C_4$ alkyl)-.

23. The compound of claim 17, wherein $R_1$ is -$CH_3$ and $R_1$' is -Cl.

24. The compound of claim 17, wherein $R_1$ is $-CH_3$ and $R_1'$ is $-OCH_3$.

25. The compound of claim 16, wherein $R_1$ and $R_1'$ are $-(C_1-C_3)$alkyl.

26. The compound of claim 25, wherein $R_1$ and $R_1'$ are $-CH_3$.

27. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

28. A composition comprising an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16 and a pharmaceutically acceptable carrier or excipient.

29. A method for treating pain, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

30. The method of claim 29, further comprising administering to the animal an effective amount of another therapeutic agent.

31. A method for treating pain, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.

32. The method of claim 31, further comprising administering to the animal an effective amount of another therapeutic agent.

33. A method for treating an addictive disorder, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

34. The method of claim 33, further comprising administering to the animal an effective amount of another therapeutic agent.

35. A method for treating an addictive disorder, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.

36. The method of claim 35, further comprising administering to the animal an effective amount of another therapeutic agent.

37. A method for treating Parkinson's disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

38. The method of claim 37, further comprising administering to the animal an effective amount of another therapeutic agent.

39. A method for treating Parkinson's disease, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.

40. The method of claim 39, further comprising administering to the animal an effective amount of another therapeutic agent.

41. A method for treating anxiety, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

42. The method of claim 41, further comprising administering to the animal an effective amount of another therapeutic agent.

43. A method for treating anxiety, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.

44. The method of claim 43, further comprising administering to the animal an effective amount of another therapeutic agent.

45. A method for treating schizophrenia, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

46. The method of claim 45, further comprising administering to the animal an effective amount of another therapeutic agent.

47. A method for treating schizophrenia, comprising administering to an animal in need thereof an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.

48. The method of claim 47, further comprising administering to the animal an effective amount of another therapeutic agent.

49. A method for inhibiting mGluR5-receptor function in a cell, comprising contacting a cell capable of expressing mGluR5 with an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

50. The method of claim 49, further comprising contacting the cell with an effective amount of another therapeutic agent.

51. A method for inhibiting mGluR5-receptor function in a cell, comprising contacting a cell capable of expressing mGluR5 with an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 16.

52. The method of claim 51, further comprising contacting the cell with an effective amount of another therapeutic agent.

53. A method for preparing a composition, the method comprising admixing a compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

54. A kit comprising a container containing the composition of claim 27.